Haemoperfusion Combined With Xuebijing Injection Improves Inflammatory Status And Prognosis In Patients With...

End-stage renal disease (ESRD) is an irreversible, chronic, progressive disease that seriously affects patients' quality of life, and clinical treatment currently faces certain challenges. A total of 100 ESRD patients from the Affiliated Hospital of North China University of Science and Technology were enrolled in this retrospective study and divided into HT and HI groups based on treatment modality. Both groups were treated with haemoperfusion, and the HI group was additionally treated with Xuebijing injection. The main assessments of the two groups were inflammatory factor indexes, immune indexes, renal function indexes, and clinical efficacy. Secondary outcomes included quality of life [Health Questionnaire (SF-36) score], complication and adverse reaction rates. Patient survival rates were calculated to analyze the correlation between microinflammatory status and prognosis. Logistic regression and receiver operating characteristic (ROC) analyses were conducted to further explore prognostic factors and predict complication risk. After treatment, the indicators in both groups differed significantly compared with the pre-treatment values (P < 0.05). Inflammatory indexes, renal function indexes, complication rates, and adverse reaction rates in the HI group were lower than those in the HT group, whereas immune indexes, clinical efficacy, SF-36 score, and survival rate were higher than those in the HT group (P < 0.05). Logistic regression analysis and ROC results showed that inflammatory indexes, immune indexes, and renal function indexes were closely associated with prognosis (P < 0.05). Combined therapy of haemoperfusion and Xuebijing shows favorable clinical efficacy in ESRD patients, improving renal function, alleviating the inflammatory response, regulating immune function, and contributing to favorable prognostic outcomes, and warrants further clinical exploration and validation.